CA2816416C - Methods and compositions for treating hiv-associated diarrhea - Google Patents

Methods and compositions for treating hiv-associated diarrhea Download PDF

Info

Publication number
CA2816416C
CA2816416C CA2816416A CA2816416A CA2816416C CA 2816416 C CA2816416 C CA 2816416C CA 2816416 A CA2816416 A CA 2816416A CA 2816416 A CA2816416 A CA 2816416A CA 2816416 C CA2816416 C CA 2816416C
Authority
CA
Canada
Prior art keywords
crofelemer
per day
placebo
day
diarrhea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2816416A
Other languages
English (en)
French (fr)
Other versions
CA2816416A1 (en
Inventor
William Forbes
Enoch Bortey
Steven King
Pravin Chaturvedi
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45994461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2816416(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of CA2816416A1 publication Critical patent/CA2816416A1/en
Application granted granted Critical
Publication of CA2816416C publication Critical patent/CA2816416C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2816416A 2010-10-31 2011-10-31 Methods and compositions for treating hiv-associated diarrhea Active CA2816416C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40862210P 2010-10-31 2010-10-31
US61/408,622 2010-10-31
US40933510P 2010-11-02 2010-11-02
US61/409,335 2010-11-02
US41624910P 2010-11-22 2010-11-22
US61/416,249 2010-11-22
US201161434379P 2011-01-19 2011-01-19
US61/434,379 2011-01-19
PCT/US2011/058549 WO2012058664A1 (en) 2010-10-31 2011-10-31 Methods and compositions for treating hiv-associated diarrhea

Publications (2)

Publication Number Publication Date
CA2816416A1 CA2816416A1 (en) 2012-05-03
CA2816416C true CA2816416C (en) 2020-02-11

Family

ID=45994461

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2816416A Active CA2816416C (en) 2010-10-31 2011-10-31 Methods and compositions for treating hiv-associated diarrhea

Country Status (20)

Country Link
US (4) US8962680B2 (https=)
EP (1) EP2632550B1 (https=)
JP (2) JP6063385B2 (https=)
CN (2) CN103370101A (https=)
AU (1) AU2011320155B2 (https=)
BR (1) BR112013010774A2 (https=)
CA (1) CA2816416C (https=)
DK (1) DK2632550T3 (https=)
EC (1) ECSP13012650A (https=)
ES (1) ES2635435T3 (https=)
HK (1) HK1249036A1 (https=)
HU (1) HUE035393T2 (https=)
MX (1) MX348184B (https=)
PE (1) PE20140036A1 (https=)
PH (1) PH12013500857A1 (https=)
PL (1) PL2632550T3 (https=)
PT (1) PT2632550T (https=)
RU (1) RU2597746C2 (https=)
WO (1) WO2012058664A1 (https=)
ZA (1) ZA201303136B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2657803C (en) * 2006-05-01 2019-01-08 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
SG195538A1 (en) 2006-05-01 2013-12-30 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
EP2632550B1 (en) 2010-10-31 2017-05-03 Napo Pharmaceuticals, Inc. Methods and compositions for treating hiv-associated diarrhea
MX2015007065A (es) * 2012-12-07 2017-03-01 Napo Pharmaceuticals Inc Metodo y composiciones para tratar diarrea asociada con vih.
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
JOP20190276B1 (ar) 2017-05-31 2024-04-18 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
JOP20190275B1 (ar) 2017-05-31 2024-12-22 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
MX2022016367A (es) * 2020-06-19 2023-01-30 Napo Pharmaceuticals Inc Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia.
WO2022115481A1 (en) * 2020-11-24 2022-06-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating post-acute infection gastrointestinal disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
EP0935417B1 (en) 1996-10-16 2009-05-06 Napo Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
WO2000047062A2 (en) 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US20040071793A1 (en) 2002-10-05 2004-04-15 Bobrowski Paul J. Oral rehydration methods and compositions
US20080025966A1 (en) * 2004-01-30 2008-01-31 Currie Mark G Methods And Compositions For The Treatment Of Gastrointestinal disorders
EP1937655A1 (en) * 2005-06-22 2008-07-02 University of Massachusetts Hiv-1 protease inhibitors, and methods of making and using them
WO2007068383A1 (en) 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating virus infections
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
CA2657803C (en) 2006-05-01 2019-01-08 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
SG195538A1 (en) 2006-05-01 2013-12-30 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
WO2010021681A2 (en) 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
PH12012500557A1 (en) 2009-08-26 2012-10-22 Glenmark Pharmaceuticals Ltd Method for producing proanthocyanidin polymer compositions for pharmaceutical formulations
AU2010303577B2 (en) * 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
US20110087530A1 (en) 2009-10-09 2011-04-14 Visa U.S.A. Inc. Systems and Methods to Provide Loyalty Programs
EP2632550B1 (en) 2010-10-31 2017-05-03 Napo Pharmaceuticals, Inc. Methods and compositions for treating hiv-associated diarrhea
WO2012101008A1 (en) 2011-01-27 2012-08-02 Glenmark Pharmaceuticals Limited Process for the production of proanthocyanidin polymeric composition
RU2014124981A (ru) 2011-12-22 2016-02-10 Гленмарк Фармасьютикалс Лимитед Неэнтеросолюбильная фармацевтическая композиция, содержащая крофелемер
MX2015007065A (es) 2012-12-07 2017-03-01 Napo Pharmaceuticals Inc Metodo y composiciones para tratar diarrea asociada con vih.

Also Published As

Publication number Publication date
US20120107370A1 (en) 2012-05-03
CN107595836A (zh) 2018-01-19
US20120184605A1 (en) 2012-07-19
US20140294903A1 (en) 2014-10-02
JP2013540826A (ja) 2013-11-07
CA2816416A1 (en) 2012-05-03
RU2597746C2 (ru) 2016-09-20
AU2011320155B2 (en) 2016-02-25
ECSP13012650A (es) 2013-10-31
MX348184B (es) 2017-06-02
HK1249036A1 (zh) 2018-10-26
JP6310971B2 (ja) 2018-04-11
JP2017019806A (ja) 2017-01-26
ZA201303136B (en) 2016-01-27
EP2632550A4 (en) 2014-04-23
AU2011320155A1 (en) 2013-05-09
PE20140036A1 (es) 2014-01-31
EP2632550A1 (en) 2013-09-04
EP2632550B1 (en) 2017-05-03
JP6063385B2 (ja) 2017-01-18
RU2013123794A (ru) 2014-12-10
PT2632550T (pt) 2017-08-02
DK2632550T3 (en) 2017-08-07
PL2632550T3 (pl) 2017-10-31
MX2013004873A (es) 2013-08-21
CN103370101A (zh) 2013-10-23
PH12013500857A1 (en) 2018-01-17
HUE035393T2 (en) 2018-05-02
BR112013010774A2 (pt) 2017-03-21
ES2635435T3 (es) 2017-10-03
US8962680B2 (en) 2015-02-24
WO2012058664A1 (en) 2012-05-03
US9585868B2 (en) 2017-03-07
US20150190367A1 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
CA2816416C (en) Methods and compositions for treating hiv-associated diarrhea
JP6159084B2 (ja) 酒さまたは赤面に関連する皮膚疾患を治療するための、ベルベリンまたはその類似体を含有する組成物
US20140163096A1 (en) Methods and compositions for treating hiv-associated diarrhea
CA3054992A1 (fr) Prevention des risques associes a un allongement de l'intervalle qt d'origine medicamenteuse a l'aide d'un inhibiteur specifique de la production de ros d'origine mitochondriale
US11857510B2 (en) Methods and compositions for treating congenital diarrhea disorder
HK1183263A (en) Methods and compositions for treating hiv-associated diarrhea
HK1183263B (en) Methods and compositions for treating hiv-associated diarrhea
CN112789052A (zh) 用于保护皮肤免受紫外线辐射的番茄红素组合物和方法
WO2022115481A1 (en) Methods and compositions for treating post-acute infection gastrointestinal disorders
HK40016516A (en) Compositions for use in treating congenital diarrhea disorder
HK40016517B (en) Compositions for treating bile acid diarrhea and short bowel syndrome
HK40016517A (en) Compositions for treating bile acid diarrhea and short bowel syndrome

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160907

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240917

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240917

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240917

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250908

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250908